Curaleaf Holdings Files 6-K, Incorporates Exhibit

Ticker: CURLF · Form: 6-K · Filed: 2024-05-10T00:00:00.000Z

Sentiment: neutral

Topics: reporting, sec-filing, compliance

TL;DR

Curaleaf filed a 6-K for Q1 2024, confirming 40-F reporting and incorporating an exhibit.

AI Summary

Curaleaf Holdings, Inc. filed a Form 6-K on May 10, 2024, reporting for the period ending March 31, 2024. The filing indicates that Curaleaf will file its annual reports under Form 40-F, not Form 20-F. Exhibit 99.1 from this filing is incorporated by reference into their Form F-10 registration statement.

Why It Matters

This filing clarifies Curaleaf's reporting obligations and incorporates specific information into their broader SEC filings, which is important for investors tracking their regulatory compliance and financial disclosures.

Risk Assessment

Risk Level: low — This is a routine filing that primarily concerns reporting procedures and incorporation by reference, with no new financial or operational information disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report for the month of May 2024 and to incorporate Exhibit 99.1 into the Company's Registration Statement on Form F-10.

Which form does Curaleaf Holdings, Inc. indicate it will file its annual reports under?

Curaleaf Holdings, Inc. indicates it will file its annual reports under Form 40-F.

What is the period of report for this filing?

The conformed period of report is March 31, 2024.

What exhibit is being incorporated by reference in this filing?

Exhibit 99.1 to this Form 6-K is being incorporated by reference.

What is the SEC file number for Curaleaf Holdings, Inc.?

The SEC file number for Curaleaf Holdings, Inc. is 333-249081.

From the Filing

0001756770-24-000033.txt : 20240510 0001756770-24-000033.hdr.sgml : 20240510 20240509181705 ACCESSION NUMBER: 0001756770-24-000033 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Curaleaf Holdings, Inc. CENTRAL INDEX KEY: 0001756770 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-249081 FILM NUMBER: 24932283 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 781-451-0117 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: LEAD VENTURES INC. DATE OF NAME CHANGE: 20181023 6-K 1 q1246-kcover.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number: 333-249081 Curaleaf Holdings, Inc. (Name of Registrant) 666 Burrard Street, Suite 1700, Vancouver, British Columbia V6C 2X8, Canada (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☐    Form 40-F ☒ INCORPORATION BY REFERENCE Exhibit 99.1 to this Form 6-K of Curaleaf Holdings, Inc. (the “Company”) are hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-269109) of the Company, as amended or supplemented. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CURALEAF HOLDINGS, INC. (Registrant) Date: May 9, 2024 By: /s/ Peter Clateman Name: Peter Clateman Title: Chief Legal Officer EXHIBIT INDEX Exhibit Number Description 99.1 Unaudited Condensed Interim Consolidated Financial Statements as of March 31, 2024 and December 31, 2023 and for the Three Months Ended March 31 , 202 4 and 202 3 and Management’s Discussion and Analysis of Financial Condition and Results of Operations and for the Three Months Ended March 31 , 202 4 and 202 3 99.2 CEO Certification of Interim Filings 99.3 CFO Certification of Interim Filings 99.4 Press Release dated May 9, 2024 EX-99.1 2 q124-exx992xfsandmda.htm EX-99.1 Document Exhibit 99.2 CURALEAF HOLDINGS, INC. Condensed Interim Consolidated Financial Statements (Unaudited) As of March 31, 2024 and December 31, 2023 and for the Three Months Ended March 31, 2024 and 2023 (Expressed in Thousands United States Dollars Unless Otherwise Stated) Page(s) Financial Statements: Condensed Interim Consolidated Balance Sheets (Unaudited) as of March 31, 2024 and December 31, 2023 3 Condensed Interim Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2024 and 2023 5 Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) for the three months ended March 31, 2024 and 2023 6 Condensed Interim Consolidated Statements of Temporary Equity and Shareholders’ Equity (Unaudited) for the three months ended March 31, 2024 and 2023 7 Condensed Interim Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2024 and 2023 8 Notes to Condensed Interim Consolidated Financial Statements (Unaudited) 10 Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2024 and 2023 52 Curaleaf Holdings, Inc. Condensed Interim Consolidated Bala

View on Read The Filing